Verismo Therapeutics

Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutics core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells. Preclinical studies show that SynKIRTM-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found...

Car-t,cell therapy,solid tumor,immuno-oncology,and kir-car platform

Verismo therapeutics operates in the Biotechnology research industry.

Verismo therapeutics's revenue is 11m - 100m

Verismo therapeutics has 11 - 50 employees.